Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Connection

Theodore Karrison to Molecular Targeted Therapy

This is a "connection" page, showing publications Theodore Karrison has written about Molecular Targeted Therapy.

 
Connection Strength
 
 
 
0.292
 
  1. Sharma MR, Joshi SS, Karrison TG, Allen K, Suh G, Marsh R, Kozloff MF, Polite BN, Catenacci DVT, Kindler HL. A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies. Cancer. 2019 05 15; 125(10):1629-1636.
    View in: PubMed
    Score: 0.157
  2. Chung EK, Posadas EM, Kasza K, Karrison T, Manchen E, Hahn OM, Stadler WM. A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma. Am J Clin Oncol. 2011 Apr; 34(2):150-4.
    View in: PubMed
    Score: 0.091
  3. Catenacci DVT, Moya S, Lomnicki S, Chase LM, Peterson BF, Reizine N, Alpert L, Setia N, Xiao SY, Hart J, Siddiqui UD, Hogarth DK, Eng OS, Turaga K, Roggin K, Posner MC, Chang P, Narula S, Rampurwala M, Ji Y, Karrison T, Liao CY, Polite BN, Kindler HL. Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. Cancer Discov. 2021 02; 11(2):308-325.
    View in: PubMed
    Score: 0.045
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.